CN109432419A - A kind of immunologic adjuvant, inactivated vaccine and preparation method thereof - Google Patents
A kind of immunologic adjuvant, inactivated vaccine and preparation method thereof Download PDFInfo
- Publication number
- CN109432419A CN109432419A CN201811564213.1A CN201811564213A CN109432419A CN 109432419 A CN109432419 A CN 109432419A CN 201811564213 A CN201811564213 A CN 201811564213A CN 109432419 A CN109432419 A CN 109432419A
- Authority
- CN
- China
- Prior art keywords
- inactivated vaccine
- vaccine
- group
- antigen
- glycerol
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5252—Virus inactivated (killed)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55577—Saponins; Quil A; QS21; ISCOMS
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55583—Polysaccharides
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10211—Aviadenovirus, e.g. fowl adenovirus A
- C12N2710/10234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16111—Influenzavirus A, i.e. influenza A virus
- C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/18011—Paramyxoviridae
- C12N2760/18111—Avulavirus, e.g. Newcastle disease virus
- C12N2760/18134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Virology (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Molecular Biology (AREA)
- Communicable Diseases (AREA)
- Immunology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Oncology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Inorganic Chemistry (AREA)
- Biochemistry (AREA)
- Engineering & Computer Science (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Pulmonology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
The present invention provides a kind of immunologic adjuvants, inactivated vaccine and preparation method thereof, belong to field of biological pharmacy for animals.Immunologic adjuvant includes saponin(e QS-21,20-100mg/mL glycerol, the 5-50mg/mL sucrose of the cation guar gum of 1.0-10mg/mL, the poloxamer of 1.0-10mg/mL, the mannatide of 1.0-10mg/mL, 1.0-10mg/mL.The immunologic adjuvant is conducive to respiratory tract and alimentary canal that vaccine is adhered to poultry, plays slow releasing function, improve the period of storage of antigen using poloxamer and cation guar gum as sustained release agent；Mannatide and saponin(e QS-21 can significantly improve mucosal immunity level as immunopotentiator；Glycerol and sucrose can protect structural stability of the antigen under body temperature, to improve the action time of antigen.For this vaccine by the way of spraying immune and oral immunity, the automation that can be realized scale livestock farming is immune, and cost of labor is greatly decreased, reduces the risk of the immuning failure of human factor.
Description
Technical field
The invention belongs to field of biological pharmacy for animals, specifically a kind of immunologic adjuvant, inactivated vaccine and preparation method thereof.
Background technique
Immunologic adjuvant, also known as nospecific immunity proliferant agent, itself does not have antigenicity, but synantigen mixes
After being injected into body, it can non-specifically change body to the specific immune response of the antigen.Immunologic adjuvant includes: tradition
Type Alum adjuvant, oil emulsion adjuvant, Freund's adjuvant, Cytokine adjuvant etc., wherein aluminium adjuvant and Freund's adjuvant are to make extensively at present
Immunity enhancement adjuvant, the mechanism of action mainly form antigen bunker in body injection site, make antigen slow release,
Thick liquid cell is stimulated to generate antibody, but aluminium adjuvant easily causes body allergic reaction and should not freeze, and the mineral in Freund's adjuvant
Oil by organism metabolism, cannot easily cause the side reactions such as inflammatory reaction, granuloma, ulcer and the fever of injection site.In addition, with
Large-scale cultivation level it is higher and higher, single cultivation quantity is continuously improved, and has reached million ranks, artificial immunity inactivation at present
Vaccine difficulty is increasing, and there is an urgent need to the vaccines independent of artificial immunity for breeding enterprise.
Summary of the invention
The object of the present invention is to provide a kind of immunologic adjuvants, inactivated vaccine and preparation method thereof.
It is an object of the invention to provided immunologic adjuvants to improve machine because of the compound synergistic effect between its component
The mucosal immunity of body is horizontal, the immune effect of enhancement antigen.
It is an object of the invention to solve the problems, such as to need artificial immunity vaccine in the prior art, this vaccine is sprayable to exempt from
Epidemic disease, also orally available immune, the automation that can be realized scale livestock farming is immune, and cost of labor is greatly decreased, reduce it is artificial because
The risk of the immuning failure of element.
To realize the above technical purpose, the present invention adopts the following technical scheme:
A kind of novel immunologic adjuvant, it is characterised in that include: cation guar gum, the 1-10mg/mL of 1-10mg/mL
Poloxamer, the mannatide of 1-10mg/mL, 1-10mg/mL saponin(e QS-21,20-100mg/mL glycerol, 5-50mg/mL
Sucrose.
Further, which includes: 5mg/mL cation guar gum, the poloxamer of 5mg/mL, 10mg/mL
Saponin(e QS-21,60mg/mL glycerol, the 25mg/mL sucrose of mannatide, 10mg/mL.Further, preparation method are as follows:
Cation guar gum, poloxamer, mannatide, saponin(e QS-21, glycerol, sugarcane are sequentially added in the solution that pH is 4-6
Sugar, and be sufficiently mixed uniformly.
Further, preparation method are as follows: cation guar gum, poloxamer, sweet is sequentially added in the solution that pH is 5
Reveal glycan peptide, saponin(e QS-21, glycerol, sucrose, and is sufficiently mixed uniformly.
Further, cation guar gum being sequentially added in the case where pH is the acid condition of 4-6, poloxamer mixes well,
Facilitate it and form thermo-responsive hydro gel, convenient for promoting the subsequent suction-operated to antigen, then adds mannatide, saponin(e
QS-21, glycerol, sucrose.
A kind of novel inactivated vaccine, it is characterised in that: the epidemic disease is added to the novel immune in claim 1 according to seedling and helps
Agent.
Further, preparation method is by immunologic adjuvant described in claim 1 and the antigen of inactivation by volume
It is mixed than 1:1-10, obtains the inactivated vaccine.
The immunization route of the further vaccine is spraying or drinking-water is immune.
Further inactivated vaccine refers to the inactivated vaccine of orthomyxovirus, the inactivated vaccine of paramyxovirus and adenovirus inactivation
Vaccine.
Further, orthomyxovirus vaccine refers to the inactivated vaccine of avian influenza virus.
Further, paramyxovirus vaccine refers to newcastle disease virus inactivated vaccine.
Further, adenovirus vaccine refers to aviadenovirus inactivated vaccine.
By adopting the above technical scheme, the device have the advantages that are as follows:
1. poloxamer and cation guar gum can form thermo-responsive hydro gel in immunologic adjuvant, wraps up and protect inactivation anti-
Original, when using drinking-water and spraying immune, above-mentioned gel can help to the respiratory tract and alimentary canal that vaccine is adhered to poultry, thus
Reach slow releasing function, improves the period of storage of antigen.
2. the saponin(e QS-21 in immunologic adjuvant has antivirus action, cell can be inhibited under the excitation of long chain polysaccharides
Proliferation, mannatide can be shown because can be used as immunocompetence of the glycogen to enhance saponin(e QS-21 both as immunopotentiator
It writes and improves mucosal immunity level, to greatly improve immune effect.
3. glycerol and sucrose can protect structural stability of the antigen under body temperature in immunologic adjuvant, to improve antigen
Action time.
4. vaccine, by the way of spraying immune and oral immunity, the automation that can be realized scale livestock farming is exempted from
Cost of labor is greatly decreased in epidemic disease, reduces the risk of the immuning failure of human factor.
Specific embodiment
Detailed description below is all exemplary, it is intended to provide further instruction to the present invention.Those skilled in the art
Member it should be understood that on the premise of without departing from the spirit and scope of the present invention can details to technical solution of the present invention and
Form is modified or is replaced, but these modifications and replacement each fall within protection scope of the present invention.
Embodiment 1: immune adjuvants and concentration, 4 type aviadenovirus inactivated vaccine of I group and its preparation and evaluation
One, the preparation of immune adjuvants；
It 1, is to sequentially add cation guar gum 1mg/mL, poloxamer 1mg/mL, mannatide in 5 solution in pH
1mg/mL, saponin(e QS-21 1mg/mL, glycerol 20mg/mL, sucrose 50mg/mL, and be sufficiently mixed uniformly, high-temperature sterilization is spare,
It is denoted as Z1.
It 2, is to sequentially add cation guar gum 5mg/mL, poloxamer 5mg/mL, mannatide in 5 solution in pH
10mg/mL, saponin(e QS-21 10mg/mL, glycerol 60mg/mL, sucrose 25mg/mL, and be sufficiently mixed uniformly, high-temperature sterilization is standby
With being denoted as Z2.
It 3, is to sequentially add cation guar gum 10mg/mL, poloxamer 10mg/mL, mannatide in 5 solution in pH
5mg/mL, saponin(e QS-21 5mg/mL, glycerol 100mg/mL, sucrose 50mg/mL, and be sufficiently mixed uniformly, high-temperature sterilization is spare,
It is denoted as Z3.
It 4, is to sequentially add poloxamer 5mg/mL, mannatide 5mg/mL, saponin(e QS-215mg/ in 5 solution in pH
ML, glycerol 60mg/mL, sucrose 25mg/mL, and be sufficiently mixed uniformly, high-temperature sterilization is spare, is denoted as Z4.
It 5, is to sequentially add cation guar gum 5mg/mL, mannatide 5mg/mL, saponin(e QS-21 in 5 solution in pH
5mg/mL, glycerol 60mg/mL, sucrose 25mg/mL, and be sufficiently mixed uniformly, high-temperature sterilization is spare, is denoted as Z5.
Two, immune adjuvants, 4 type aviadenovirus inactivated vaccine of I group and its preparation and evaluation
1, prepared by 4 type aviadenovirus inactivated vaccine of I group
Be by above-mentioned label~to spread antibody (AGP) with potency agar two-phase after inactivation respectively be 1 for the immunologic adjuvant of Z5:
1:5 is mixed 16 inactivation antigen by volume, as 4 type aviadenovirus inactivated vaccine of the I of Y1~Y5 group.
2, the safety detection of 4 type aviadenovirus inactivated vaccine of I group
With 7 age in days SPF chicken, 10 plumage, every drinking-water 1ml (labeled as the vaccine of Y1) is observed 14, sees whether immune draw
Any locally and systemically adverse reaction risen.The results show that owning after prepared 4 type aviadenovirus inactivated vaccine of I group is immune
Test chicken spirit, feeding and drinking-water are showed no exception.
3, the immuning effect test of 4 type aviadenovirus inactivated vaccine of I group
7 age in days SPF chicken, 60 plumage is taken, is randomly divided into six groups, after temporarily supporting one, is proceeded as follows respectively:
The first~five group is set as inactivated vaccine group, every group of 4 type aviadenovirus inactivated vaccine of I group for being immunized Y1~Y5 respectively,
It drinks water again after 14 days and vaccine prepared by 0.5mL is immunized.
6th group is set as blank control group.
The above-mentioned tested chicken of each group exempt from two after 14 days, every plumage chicken attacks malicious 0.5mL with the virulent drinking-water of the FAVRP-8 strain of 1ml.
As a result: first group of 9 protection, second group of all protection, third group 9 protections, the 4th group of 3 protections, the 5th group 4
It only protects, the 6th group of all morbidity, the results showed that prepared 4 type aviadenovirus inactivated vaccine of Y1~Y3I group, which is capable of providing, to be filled
The protection divided；In addition, simultaneously containing the adjuvant of cation guar gum and poloxamer preparation inactivated vaccine can provide it is higher
Protection, and contain only cation guar gum or contain only poloxamer adjuvant preparation vaccine sufficient protection cannot be provided.
Embodiment 2: influence of the different pH environment to immunologic adjuvant, 4 type aviadenovirus inactivated vaccine effect of I group
One, the preparation of the immunologic adjuvant of different pH value
1. being to sequentially add cation guar gum 5mg/mL, poloxamer 5mg/mL, mannatide in 3 solution in pH
5mg/mL, saponin(e QS-21 5mg/mL, glycerol 60mg/mL, sucrose 25mg/mL, and be sufficiently mixed uniformly, high-temperature sterilization is spare,
It is denoted as P1.
2. in the solution that pH is respectively 4,5,6,7, sequentially add the reagent of above-mentioned prescription strength, and be denoted as P2, P3,
P4,P5；
Two, influence of the difference pH environment to immunologic adjuvant, the evaluation of 4 type aviadenovirus inactivated vaccine of I group
1, prepared by 4 type aviadenovirus inactivated vaccine of I group
Be by above-mentioned label~to spread antibody (AGP) with potency agar two-phase after inactivation respectively be 1 for the immunologic adjuvant of P5:
1:5 is mixed 16 inactivation antigen by volume, as 4 type aviadenovirus inactivated vaccine of the I of M1~M5 group.
2, the safety detection of 4 type aviadenovirus inactivated vaccine of I group
With 7 age in days SPF chicken, 10 plumage, every drinking-water 1ml (labeled as the vaccine of M1) is observed 14, sees whether immune draw
Any locally and systemically adverse reaction risen.The results show that owning after prepared 4 type aviadenovirus inactivated vaccine of I group is immune
Test chicken spirit, feeding and drinking-water are showed no exception.
3, the immuning effect test of 4 type aviadenovirus inactivated vaccine of I group
7 age in days SPF chicken, 60 plumage is taken, is randomly divided into six groups, after temporarily supporting one, is proceeded as follows respectively:
The first~five group is set as inactivated vaccine group, every group of 4 type aviadenovirus inactivated vaccine of I group for being immunized M1~M5 respectively,
It drinks water again after 14 days and vaccine prepared by 0.5mL is immunized.
6th group is set as blank control group.
The above-mentioned tested chicken of each group exempt from two after 14 days, every plumage chicken attacks malicious 0.5mL with the virulent drinking-water of the FAVRP-8 strain of 1ml.
As a result: first group 3 protection, second and third, four groups all protection, the 5th group 4 protection, the 6th group all morbidity,
Show in the environment of pH4-6, facilitates immunologic adjuvant and play immune efficacy, reach optimal immune effect.
Embodiment 3: immunologic adjuvant, newcastle disease and bird flu bivalent inactivated vaccine and its preparation and evaluation
1, immunologic adjuvant configures
Cation guar gum 5mg/mL, poloxamer 5mg/mL, mannatide are sequentially added in the solution that pH is 5
5mg/mL, saponin(e QS-21 5mg/mL, glycerol 20mg/mL, sucrose 50mg/mL, and be sufficiently mixed uniformly, high-temperature sterilization is spare.
2, newcastle disease and the preparation of bird flu bivalent inactivated vaccine
It is blood after the newcastle disease inactivation antigen of 1:64 and inactivation by antigen hemagglutinating antigen (HA) after immunologic adjuvant described in 1 and inactivation
1:10 is mixed the inactivation antigen that solidifying antigen (HA) is 1:128 by volume, as newcastle disease and bird flu bivalent inactivated vaccine.
3, the safety detection of newcastle disease and bird flu bivalent inactivated vaccine
With 7 age in days SPF chicken, 10 plumage, every drinking-water 1ml is observed 14, see whether it is immune caused by any part and complete
Body adverse reaction.The results show that all test chickens are spiritual, adopt after prepared newcastle disease and bird flu bivalent inactivated vaccine is immune
Food and drinking-water are showed no exception.
2.4: the immuning effect test of newcastle disease and bird flu bivalent inactivated vaccine
7 age in days SPF chicken, 40 plumage is taken, is randomly divided into 4 groups, after temporarily supporting one, is proceeded as follows respectively:
First group: being set as blank control group.
Second group: being set as blank control group.
Third group: being set as inactivated vaccine group, and every plumage, which is drunk water, is immunized newcastle disease prepared by 0.5mL and the inactivation of bird flu bigeminy
Vaccine, vaccine prepared by immune 0.5mL of drinking water again after 14 days.
4th group: being set as inactivated vaccine group, every plumage, which is drunk water, is immunized newcastle disease prepared by 0.5mL and the inactivation of bird flu bigeminy
Vaccine, vaccine prepared by immune 0.5mL of drinking water again after 14 days.
Above-mentioned first group and the tested chicken of third group exempt from two after 14 days, every plumage chicken attacks poison with the virulent drinking-water of NDV of 1ml
0.5mL。
Above-mentioned second group and the 4th group of tested chicken exempt from two after 14 days, every plumage chicken is attacked with the virulent drinking-water of H9 hypotype AIV of 1ml
Malicious 0.5mL.
As a result: first group of 8 morbidity, second group of 9 morbidity, third group 9 protections, the 4th group of 10 protections show institute
The newcastle disease and bird flu bivalent inactivated vaccine of preparation are capable of providing sufficient protection.
Embodiment 4: the inactivated avian influenza vaccine and oil emulsion inactivated vaccine effect of this formulation auxiliary preparation compare
1, immunologic adjuvant configures
It is to sequentially add cation guar gum 10mg/mL, poloxamer 5mg/mL, mannatide in 4 solution in PH
10mg/mL, saponin(e QS-21 10mg/mL, glycerol 25mg/mL, sucrose 5mg/mL, and be sufficiently mixed uniformly, high-temperature sterilization is spare.
2, prepared by inactivated avian influenza vaccine
By above-mentioned immunologic adjuvant, 1:10 is mixed by volume with inactivation antigen that antigen hemagglutinating antigen after inactivation (HA) is 1:128 respectively
It is even, as inactivated avian influenza vaccine.
Oil emulsion inactivated vaccine is commercially available AI oil-adjuvant inactivated vaccine.
3, the immune efficacy comparative test of different adjuvants and different mode inactivated avian influenza vaccines of being excused from an examination
7 age in days SPF chicken, 30 plumage is taken, 3 groups is randomly divided into, every group 10, after temporarily supporting one, proceeds as follows respectively:
First group: it is set as novel adjuvant vaccine group, every plumage, which is drunk water, is immunized inactivated avian influenza vaccine prepared by 0.5mL, and 14
It drinks water again after it and vaccine prepared by 0.5mL is immunized.
Second group: being set as oil emulsion inactivated vaccine group, every plumage is subcutaneously injected vaccine 0.5mL, is subcutaneously injected again after 14 days
Vaccine 0.5mL.
Third group: it is set as blank control group.
Above-mentioned three groups of tested chickens exempt from two after 14 days, every plumage chicken attacks poison with the virulent collunarium of the bird flu of 0.5ml.
As a result: first group of 9 protection, second group of 9 protection, third group 9 morbidities show that mucosal immunity novel adjuvant goes out
Live vaccine can have the immune protection effectiveness equivalent with oil emulsion inactivated vaccine.
Embodiment 5:
Referring to the test method of embodiment 4, the immunization route of inactivated vaccine described in this case is changed to spraying immune, is tested
Similar Vaccine effectiveness is immunized with drinking-water the results show that having.
Claims (9)
1. a kind of novel immunologic adjuvant, it is characterised in that include: the pool of the cation guar gum of 1-10mg/mL, 1-10mg/mL
Saponin(e QS-21,20-100mg/mL glycerol, the 5-50mg/mL sugarcane of the mannatide of Luo Shamu, 1-10mg/mL, 1-10mg/mL
Sugar.
2. immunologic adjuvant according to claim 1, it is characterised in that include: 5mg/mL cation guar gum, 5mg/
The poloxamer of mL, the mannatide of 10mg/mL, 10mg/mL saponin(e QS-21,60mg/mL glycerol, 25mg/mL sucrose.
3. a kind of preparation method of immunologic adjuvant, it is characterised in that: sequentially add prescription strength in the solution of pH4-6
Cation guar gum, poloxamer, mannatide, saponin(e QS-21, glycerol, sucrose, and be sufficiently mixed uniformly.
4. the preparation method of immunologic adjuvant according to claim 3, it is characterised in that: pH be 5 solution according to
Secondary cation guar gum, poloxamer, mannatide, saponin(e QS-21, the glycerol, sucrose that prescription strength is added, and it is sufficiently mixed
It closes uniform.
5. a kind of novel inactivated vaccine, it is characterised in that: the vaccine includes inactivation antigen and novel assistant described in claim 1
Agent.
6. inactivated vaccine according to claim 5, it is characterised in that: in the inactivated vaccine immunologic adjuvant with go out
The volume ratio of active antigen is 1:1-10.
7. inactivated vaccine according to claim 5, it is characterised in that: the immunization route of the inactivated vaccine be it is spraying or
Drinking-water is immune.
8. inactivated vaccine according to claim 5, it is characterised in that: the antigen of the inactivated vaccine refers to the just viscous of inactivation
The adenovirus of the paramyxovirus or/and inactivation of virus or/and inactivation.
9. inactivated vaccine according to claim 8, it is characterised in that: the orthomyxovirus refers to avian influenza virus, institute
The paramyxovirus stated refers to that newcastle disease virus, the adenovirus refer to aviadenovirus.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201811564213.1A CN109432419B (en) | 2018-12-20 | 2018-12-20 | Immunologic adjuvant, inactivated vaccine and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201811564213.1A CN109432419B (en) | 2018-12-20 | 2018-12-20 | Immunologic adjuvant, inactivated vaccine and preparation method thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN109432419A true CN109432419A (en) | 2019-03-08 |
| CN109432419B CN109432419B (en) | 2022-04-22 |
Family
ID=65559834
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201811564213.1A Active CN109432419B (en) | 2018-12-20 | 2018-12-20 | Immunologic adjuvant, inactivated vaccine and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN109432419B (en) |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20050123550A1 (en) * | 2003-05-12 | 2005-06-09 | Laurent Philippe E. | Molecules enhancing dermal delivery of influenza vaccines |
| CN101500937A (en) * | 2006-08-11 | 2009-08-05 | 万能药生物有限公司 | Particles for delivery of active ingredients, process of making and compositions thereof |
| CN102166356A (en) * | 2011-04-12 | 2011-08-31 | 西安交通大学 | Application of alpha-mannatide as vaccine adjuvant and vaccine preparation prepared using same |
| US20120288552A1 (en) * | 2008-03-24 | 2012-11-15 | Moti Harel | Compositions and methods for encapsulating vaccines for the oral vaccination and boostering of fish and other animals |
| CN106267183A (en) * | 2015-06-09 | 2017-01-04 | 普莱柯生物工程股份有限公司 | Live vaccine composition containing adjuvant and its preparation method and application |
-
2018
- 2018-12-20 CN CN201811564213.1A patent/CN109432419B/en active Active
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20050123550A1 (en) * | 2003-05-12 | 2005-06-09 | Laurent Philippe E. | Molecules enhancing dermal delivery of influenza vaccines |
| CN101500937A (en) * | 2006-08-11 | 2009-08-05 | 万能药生物有限公司 | Particles for delivery of active ingredients, process of making and compositions thereof |
| US20120288552A1 (en) * | 2008-03-24 | 2012-11-15 | Moti Harel | Compositions and methods for encapsulating vaccines for the oral vaccination and boostering of fish and other animals |
| CN102166356A (en) * | 2011-04-12 | 2011-08-31 | 西安交通大学 | Application of alpha-mannatide as vaccine adjuvant and vaccine preparation prepared using same |
| CN106267183A (en) * | 2015-06-09 | 2017-01-04 | 普莱柯生物工程股份有限公司 | Live vaccine composition containing adjuvant and its preparation method and application |
Also Published As
| Publication number | Publication date |
|---|---|
| CN109432419B (en) | 2022-04-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2469568T3 (en) | Flu vaccine | |
| CN105992593B (en) | Liquid stable poultry virus vaccines | |
| Lo et al. | Antibody response to a two-dose influenza vaccine regimen in adult lymphoma patients on chemotherapy | |
| JP2017506643A (en) | Liquid stable porcine virus vaccine | |
| RU2498818C2 (en) | Composition containing chitosan for ocular administration of vaccine (vaccines) to poultry | |
| EA024250B1 (en) | Dose volume of immunogenic influenza preparation for human use and vaccine comprising the same, methods for preparing them and use thereof for the treatment or prevention of diseases caused by influenza virus in humans | |
| CN102858333A (en) | Treatment of respiratory disorders | |
| RU2009126604A (en) | VACCINE AGAINST SALMONELLA | |
| Ganapathy et al. | Vaccination of commercial broiler chicks against avian metapneumovirus infection: a comparison of drinking-water, spray and oculo-oral delivery methods | |
| CN103209990B (en) | Recombinant hemagglutinin protein of influenza virus and vaccine containing the same | |
| CN101732716B (en) | Antigen-antibody complex for preventing and/or treating avian influenza | |
| MX2011004840A (en) | Vaccine compositions. | |
| ES2664236T3 (en) | Procedure to provide protective immunity against heterologous strains of Leptospira | |
| Cox et al. | A cell‐based H7N1 split influenza virion vaccine confers protection in mouse and ferret challenge models | |
| CN109432419A (en) | A kind of immunologic adjuvant, inactivated vaccine and preparation method thereof | |
| Curtiss III | The impact of vaccines and vaccinations: challenges and opportunities for modelers | |
| TW200927928A (en) | Inactivated influenza vaccine | |
| RU2378017C2 (en) | Emulsion inactivated associated vaccine against cattle rednose and coronoviral infection | |
| CN1384119A (en) | Composite yolk antibody for resisting fowl's viral blight and its prepn and application | |
| Worrall et al. | Sialivac: An intranasal homologous inactivated split virus vaccine containing bacterial sialidase for the control of avian influenza in poultry | |
| KR20220041142A (en) | Composition for mucosal administration to birds | |
| TWI580786B (en) | Vaccine of avian VII genotype new disease and its preparation method | |
| MXPA02006169A (en) | Method of improving hatchability of eggs. | |
| CN104248761A (en) | Vaccine composition, and preparation method and application thereof | |
| US20220040289A1 (en) | Rabies Composition Comprising Pika Adjuvant |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |